*#MicrobiomeTherapy**

Can the gut microbiota revolutionize cancer treatment? Insights from the 8th Asia Microbiome Conference (#AMC), held by IBC Academia Sinica, National Taiwan University Hospital, and 圖爾思生物科技 BIOTOOLS CO., LTD., shed light on the potential of next-generation #microbiome therapy in clinical applications.

Dr. Tzu-Ching Meng (孟子青) and his team at Academia Sinica, Taiwan analyzed stool samples from 134 colorectal cancer patients, revealing dietary and lifestyle interventions that may improve gut microbiota composition. Deputy Superintendent Dr. Hsiu-Chi Cheng (鄭修琦) from National Cheng Kung University Hospital highlighted the role of next-generation probiotics (#NGP) in gastric cancer treatment, showcasing their potential to reduce inflammatory markers and enhance gastric mucin secretion.

Moreover, Dr. Hsin-Chih Lai (賴信志), General Manager of REVIVEBIO CO., discussed the development trends of next-generation probiotics and their potential as food supplements with lower regulatory barriers and faster development cycles. The focus is shifting towards multi-strain probiotics and leveraging #postbiotics for therapeutic applications, paving the way for innovative approaches in immune-oncology.

Explore the full article: https://lnkd.in/gfCd3vHJ

Follow #Globalbio for more updates!